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Abstract
Muscular weakness and muscle wasting may often be observed in critically ill patients on intensive care units (ICUs) and may
present as failure to wean from mechanical ventilation. Importantly, mounting data demonstrate that mechanical ventilation
itself may induce progressive dysfunction of the main respiratory muscle, i.e. the diaphragm. The respective condition was
termed ‘ventilator-induced diaphragmatic dysfunction’ (VIDD) and should be distinguished from peripheral muscular weakness
as observed in ‘ICU-acquired weakness (ICU-AW)’.
Interestingly, VIDD and ICU-AW may often be observed in critically ill patients with, e.g. severe sepsis or septic shock, and re-
cent data demonstrate that the pathophysiology of these conditions may overlap. VIDD may mainly be characterized on a his-
topathological level as disuse muscular atrophy, and data demonstrate increased proteolysis and decreased protein synthesis
as important underlying pathomechanisms. However, atrophy alone does not explain the observed loss of muscular force.
When, e.g. isolated muscle strips are examined and force is normalized for cross-sectional ﬁbre area, the loss is
disproportionally larger than would be expected by atrophy alone. Nevertheless, although the exact molecular pathways for
the induction of proteolytic systems remain incompletely understood, data now suggest that VIDD may also be triggered by
mechanisms including decreased diaphragmatic blood ﬂow or increased oxidative stress. Here we provide a concise review
on the available literature on respiratory muscle weakness and VIDD in the critically ill. Potential underlying pathomechanisms
will be discussed before the background of current diagnostic options. Furthermore, we will elucidate and speculate on poten-
tial novel future therapeutic avenues.
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Introduction
Historically, respiratory muscle weakness during mechanical
ventilation was recognized a state of muscular fatigue. It
was thought to be caused by prolonged increased work of
breathing. Although ﬁrst reports of diminished myoﬁbre
cross-sectional area in diaphragms because of long term me-
chanical ventilation date back to the 1980s,1 direct harmful
effects of mechanical ventilation on respiratory muscles were
only thoroughly studied, e.g. in animal models in the last two
decades. Currently, respective ﬁndings from animal models
can partially be reproduced in human experiments and ﬁnd
their way to the clinical bedside.2 Within the complex of crit-
ical illness-related weakness,3–5 the dysfunction of respira-
tory muscles, particularly of the diaphragm, represents a
highly relevant and distinct clinical problem in intensive care
units (ICUs). From a clinical perspective, diaphragmatic dys-
function contributes to difﬁcult weaning or even failure to
wean from mechanical ventilation in ICU patients. Overall,
data indicate that weaning failure may affect up to 25% of
mechanically ventilated patients in ICUs today.6
Ventilator-induced diaphragmatic dysfunction (VIDD) was
previously deﬁned as loss of diaphragmatic force-generating
capacity speciﬁcally related to the use of mechanical
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ventilation.7 VIDD may typically be observed after variable
periods of controlled mechanical ventilation (i.e. ventilation
without spontaneous breathing)7,8 while assisted ventilation
modes (i.e. ventilation with preserved diaphragmatic contrac-
tions) attenuate the detrimental effects of controlled me-
chanical ventilation on the diaphragm and seem protective
in animal models9–12 unless high levels of support are used.8
As preserved muscle activity is protective, it seems conceiv-
able that diaphragmatic contractile inactivity may be the
cause for the development of VIDD.13 Despite the terminol-
ogy ‘VIDD’, the condition does not exclusively affect the major
respiratory muscle (i.e. the diaphragm), but may also involve
the intercostal musculature to a minor degree.14,15 The dia-
phragm, however, seems particularly prone to dysfunction
under mechanical ventilation while auxiliary respiratory mus-
cles, e.g. pectorales muscles,16 or skeletal limb muscles (e.g.
soleus or extensor digitorum muscles) are typically
spared.17–20
While many of the pathophysiological aspects of VIDD that
were found in animals have also been successfully
reproduced in humans, the proof of decreased force genera-
tion was so far only performed indirectly in mechanically ven-
tilated patients.21 Only very recently, direct force generation
of isolated human muscle ﬁbres was studied with ambiguous
results.22–24
Pathophysiology of respiratory muscles
dysfunction and VIDD: histological and
structural changes
The pathophysiology of VIDD was to a large extent elucidated
in models of healthy animals. Under continuous controlled
mechanical ventilation, the diaphragm partially loses its
force- and pressure-generating capacity, classically assessed
in intact animal models with trans-diaphragmatic pressure
under maximal phrenic nerve stimulation.25–27 Data demon-
strate that loss of respective force may reach up to 50%
within a few days. Importantly, the onset and time course
of VIDD may vary between the respective species stud-
ied.25–27 This makes transfer of respective data to the human
bedside particularly difﬁcult. However, loss of force seems
neither linked to age28 nor to changes in lung volumes26
nor to positive end-expiratory pressure (PEEP).27,29 In addi-
tion, phrenic nerve signal transmission and signal transduc-
tion at the neuromuscular endplate in VIDD appear normal.
This is a distinct difference between VIDD and
polyneuropathic forms of ICU-acquired weakness (ICU-AW),5
as the latter often shows conduction abnormalities in electro-
physiological studies. Moreover, loss of force is reproducible
in isolated muscle specimens,18,29 rendering the pathophysio-
logical changes of VIDD to a cellular level. Besides ultrastruc-
tural muscle ﬁbre injury,14,27,30 the most common
histopathological correlate is muscle atrophy.14,18,26,31–33 This
is especially the case in regard to type II (fast twitch) muscle
ﬁbres within the early course of the disease.14,19 Remodelling
processes with a histopathological increase of hybrid ﬁbres at
the expense of (slow twitch) type I ﬁbres can be identiﬁed at
later stages.31 However, it must be noted that atrophy alone
does not explain the observed loss of force. When force is
normalized for cross-sectional area of isolated muscle strips
(so-called speciﬁc force or tension), the loss is
disproportionally larger than would be expected by atrophy
alone.18,27,34
Overall, protein synthesis in the diaphragm in established
VIDD seems dramatically decreased.35 In murine models, pro-
teolysis is activated as early as 6 h after initiation of con-
trolled mechanical ventilation36 and loss in myosin heavy
chain synthesis of up to 65% may be observed.19,35 A de-
crease in anabolic signalling including pathways via insulin
like growth factor-1 (IGF-1)32 and myogenin (MyoD) are
found.37 Proteolysis is signiﬁcantly increased.19,38 All four
proteolytic systems of the mammalian cell are activated in
animal models of VIDD and later found induced in mechani-
cally ventilated humans.39 Proteolysis is mediated by the
calpain 19 and caspase system,40,41 as well as the ubiquitin–
proteasome complex33,38 and the autophagy–lysosomal sys-
tem.42 The biochemical changes of VIDD, mainly examined
in healthy murine models, may be augmented or even trig-
gered by oxidative stress pathways,19,43–45 nuclear factor kB
(NFkB),46,47 or JAK–Stat signalling pathways.48 Similar to pa-
tients with severe sepsis and septic shock, distinct cytokine
cascades are upregulated. This includes interleukin (IL)-6, tu-
mour necrosis factor-α, and IL-1β in rat diaphragmatic tissue
exposed to mechanical ventilation47 and may further amplify
major inﬂammatory signalling pathways including NFkB.47,49
This ‘humoral’ response is well known to promote systemic
immune cellular consequences and may also result in im-
mune phenotypic changes.50–52 There is experimental proof
of diaphragmatic dysfunction directly induced by sepsis.53–57
This includes free radicals, mitochondrial dysfunction,54
calpain,56 and caspase activation.57 In addition, clinical evi-
dence points to severe sepsis/septic shock as an important
risk factor for diaphragmatic dysfunction.58,59 Interestingly,
Maes and colleagues have developed a lipopolysaccharide
rat model of controlled mechanical ventilation. They could
now show that controlled mechanical ventilation potentiates
sepsis-induced diaphragm dysfunction, possibly because of
increased pro-inﬂammatory cytokine production, autophagy,
and worsening of oxidative stress.60 To our knowledge, this
is the ﬁrst study of VIDD in a sepsis model that may indicate
an important pathophysiological overlap. It should be clearly
noticed that VIDD and sepsis induced diaphragmatic dysfunc-
tion are distinctive pathological entities13 and the ﬁndings of
overlapping pathophysiology are controversial, even more so
as mechanical ventilation was shown to protect rat dia-
phragms in sepsis.61 Nevertheless, this shared
2 D. Berger et al.
© 2016 The Authors. Published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. (2016)
DOI: 10.1002/jcsm.12108
pathophysiology may offer therapeutic options in the future.
Strategies to modulate the systemic cytokine and/or immune
response by, e.g. blocking respective cascades or by improv-
ing host defence, may in theory be beneﬁcial.62–64 However,
because of current lack of respective trials, this remains spec-
ulative at this point in time.65
Recent data indicate a profound reduction in diaphrag-
matic blood ﬂow in VIDD.66 It is therefore speculated that re-
duced oxygen delivery may lead to formation of reactive
oxygen species with consecutive triggering of proteolytic cas-
cades and enhanced oxidative stress.67 Angiogenetic factors
change their expression proﬁle under mechanical ventilation
[downregulation of vascular endothelial growth factor
(VEGF), upregulation of hypoxia-inducible factor (HIF)-1α],
but their role in VIDD remains incompletely understood.47,68
Exercise training or a genetically high aerobic capacity—in-
teresting in the context of decreased blood supply—may pro-
tect the diaphragm from VIDD. Up-regulation of heat shock
proteins and improved antioxidant properties of a ‘trained di-
aphragm’ with decreased activation of proteases and respec-
tive mitochondrial ‘protection’ are among the postulated
mechanisms.69,70 Nevertheless, mechanical ventilation may
also enhance anti-oxidative pathways, potentially as a
counter-regulatory measure.68,71 Overall, this aspect of VIDD
may open new therapeutic avenues as the redox state of a
cell might theoretically be inﬂuenced positively.71 Recent
data indicate protection from diaphragmatic weakness with
N-acetylcysteine via augmented autophagosome formation
in mice.72
Data from animal VIDD models demonstrate a quick and
complete recovery within hours if spontaneous breathing is
resumed early. However, this needs to be interpreted before
the background of limited times of mechanical ventilation
(12 to 27 h.).73–75 Moreover, the respective kinetics and time
course of VIDD are species dependent,7 and data may there-
fore not be easily transferrable between species. As patho-
physiology of VIDD was investigated mainly in models of
healthy animals, it must be kept in mind that in critically ill
patients, underlying comorbidities may contribute to dia-
phragmatic dysfunction.
Pathophysiology of respiratory muscle
dysfunction and VIDD: translation to
the bedside
Human data are basically available from two groups of pa-
tients. The bulk of evidence derives from mechanically venti-
lated brain dead organ donors. Only very recently, studies
were expanded to mixed ICU populations with underlying dis-
eases. Levine and colleagues could show in a seminal study in
14 brain death organ donors that disuse atrophy may occur
shortly after start of controlled mechanical ventilation.16
When compared to controls (i.e. patients with thoracic sur-
gery on 3 h of CMV), muscle biopsies of the costal diaphragm
in organ donors (mechanically ventilated for 18 to 69 h) ex-
hibit strongly decreased cross-sectional areas of slow-twitch
and fast-twitch ﬁbres (57% vs. 53%, respectively). Atrophy
was associated with reduced glutathione levels and up-
regulation of caspase-3 and ubiquitin ligases. These changes
were limited to the diaphragm and not reproducible, e.g. in
pectorales muscles.16 Findings were later conﬁrmed and
linked to up-regulation of autophagic systems via transcrip-
tion factors (e.g. FOXO-1), activation of the ubiquitin–
proteasome complex, NFkB activity, and induction of the
calpain system in mechanically ventilated human muscles
and diaphragms.76–80 Hooijman lately documented the acti-
vation of the ubiquitin–proteasome complex in a mixed pop-
ulation of critically ill patients.22 While direct force loss (i.e.
loss of performance of isolated muscle strips) is extensively
documented in animal models, the condition in humans was
until recently only indirectly characterized by airway occlu-
sion pressure responses to phrenic nerve stimulation.81,82 In
the last year, ﬁrst reports of human muscle ﬁbres appeared
and ﬁnally documented a loss of speciﬁc force in mechani-
cally ventilated human muscles.22–24 But a clear distinction
of the studied populations should be noted. Hooijman ini-
tially found no evidence for diminished contractile perfor-
mance in sarcomeres when studying specimens from brain
death organ donors (mean duration of mechanical ventilation
of 26 ± 5 h),23 whereas the group later published data from
mixed ICU populations suffering from comorbidities like sep-
sis or trauma (duration of mechanical ventilation 14 to 607 h)
with contractile weakness of human diaphragmatic muscle ﬁ-
bres.22,24 It is unclear to what extent these underlying condi-
tions have contributed to the documented weakness. So,
speaking in strict terms, the formal proof of contractile weak-
ness caused by mechanical ventilation is not yet established.
VIDD appears to be associated with mitochondrial dysfunc-
tion. Mechanical ventilation may alter mitochondrial respira-
tory chain enzyme function (e.g. cytochrome-c oxidase), may
induce micro-deletions within mitochondrial DNA, and may
decrease levels of mitochondrial scavengers for reactive oxy-
gen species (ROS) culminating in diaphragmatic lipid over-
load. This metabolic oversupply of resting diaphragms could
again trigger ROS production. However, these ﬁndings could
not be reproduced in biceps muscle specimens.83 A causative
link between lipid overload and mitochondrial dysfunction is
not ﬁrmly established.84 Nevertheless, oxidative stress has
been linked to activation of apoptic, proteasomal, and
autophagocytic pathways,85 and expression of angiogenetic
factors varies with the ventilation mode used.86
In conclusion, histopathological and biochemical changes
of respiratory muscle dysfunction/VIDD in animal models
could now be reproduced to some extent in human experi-
ments.2 Loss of speciﬁc force in isolated human muscle ﬁbres
has ﬁnally been documented22,24 in mixed ICU populations
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with underlying comorbidities (but not in brain death organ
donors23). With VIDD animal models available, this may open
up new options for development of speciﬁc therapeutic ap-
proaches in order to treat or prevent respiratory muscle
dysfunction/VIDD.
Clinical approaches to respiratory
muscle dysfunction/VIDD
VIDD is diagnosed by exclusion of other causes of weaning
failure (e.g. decompensated congestive heart failure) and
other speciﬁc causes of diaphragmatic weakness such as elec-
trolyte disturbances, malnutrition, drugs, central nervous sys-
tem disorders, and distinct neuromuscular disorders.7 Global
tests of respiratory muscle strength like measurement of
maximum inspiratory pressures87 or the rapid shallow breath-
ing index (respiratory rate divided by tidal volume)88 serve as
screening tools. However, they lack speciﬁcity. Assessment of
trans-diaphragmatic pressure in combination with transder-
mal phrenical nerve (magnetic) stimulation may be consid-
ered the gold standard.82,89,90 However, this approach is
invasive with the need for an oesophageal and gastric bal-
loon. Alternatively, twitch tracheal airway pressure avoids
balloon placement,81,82,91 but the accuracy of this approach
is debated.92 The electrophysiological assessment of dia-
phragmatic electrical activity via a modiﬁed nasogastric tube
(EAdi)93,94 is a new promising but almost unexplored tech-
nique for VIDD. The electromyographic signal describes the
summation amplitude of electrical activity and allows assess-
ment of neuronal respiratory drive and estimation of neuro-
ventilatory efﬁciency (tidal volume divided by electrical activ-
ity).94–97 Although there is lack of speciﬁc VIDD studies, this
approach may hold potential for respiratory monitoring as it
incorporates the neuronal feedback loop of the respiratory
drive.93,94,97 Further studies are warranted.
A non-invasive modality for patients with suspected dia-
phragmatic weakness is ultrasound, readily available at the
bedside and most likely free from adverse effects (Figures 1
and 2). With reference values established, ultrasound allows
both reproducible assessment98 of diaphragmatic function
and structure and may exclude alternative causes of weaning
failure.94,99–102 The inspiratory downward motion of the dia-
phragm should be greater than one centimetre (Figure 1).
This was evaluated in ventilated patients during spontaneous
breathing trials and predicts successful weaning with an accu-
racy similar to the rapid shallow breathing index.103 A thick-
ening fraction (inspiratory minus expiratory thickness
divided by expiratory thickness) of ≥30% was shown to exert
a positive predictive value of 91% for weaning success104
(Figure 2A and 2B). A sustained loss of diaphragmatic thick-
ness was reported for patients undergoing prolonged mechan-
ical ventilation, most prominent in the ﬁrst three days.105
Changes in thickness may be associated with diaphragmatic
weakness.106
The consequences of application of PEEP (inducing caudal
diaphragm displacement) remain unknown.107 As ultrasound
allows dynamic assessment of the diaphragm, it will mainly
provide useful insight if performed during unassisted breath-
ing, i.e. during spontaneous breathing trials.108 Recent data
indicate that the thickening fraction is also of use under me-
chanical ventilation, as thickening is caused by muscular con-
traction, but not by passive inhalation.98 Despite a growing
body of evidence for the use of ultrasound, it remains a pure
imaging technique without direct assessment of ventilation
or diaphragmatic force. Ultrasound may also be of limited
value in the early course of critical illness, when controlled
ventilation needs to be applied.94 For technical details, please
refer to ﬁgure legends (Figures 1 and 2).
VIDD management: a role for
ventilatory and pharmacological
interventions?
Human data on interventions for VIDD are sparse. When
choosing ventilatory modes, spontaneous breathing efforts
during mechanical ventilation seem protective for VIDD in
healthy animals.12,109,110 As most studies on VIDD were per-
formed in healthy animals, questions remain about the appli-
cability in the acute phase of critical illness.39 The complex
Figure 1 Assessment of diaphragmatic motion (motion mode, phased ar-
ray 3.5–5Mhz transducer). Sub-costal position (mid-clavicular line, angle
of >70° in supine subjects) with visualization of the posterior diaphrag-
matic third. The diaphragmatic dome should be hit perpendicularly.
Liver/spleen may be used as sound windows for right/left hemi-dia-
phragm. Diaphragmatic dome excursion at rest should be ≥1 cm (lower
limit of normal in healthy controls).101,108 Inspiratory diaphragmatic posi-
tion (solid line), expiratory position (dotted line), and excursion (arrow)
are indicated.
4 D. Berger et al.
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and dynamic pathophysiology of respiratory support during
critical illness asks for an individually tailored approach. Early
in acute critical illness, controlled mechanical ventilation may
often be mandatory, but an early switch to an assisted mode
seems clearly desirable. Diaphragmatic inactivity is consid-
ered to initiate VIDD.13 Interventions like intermittent sponta-
neous breathing or respiratory muscle training might be of
beneﬁt. Diaphragmatic contractions via phrenic nerve pacing
have been successfully used in tetraplegic patients111,112 and
during cardiothoracic surgery113 with documented increases
in mitochondrial respiration.114 While short periods of inter-
mittent spontaneous breathing had little effect in a rodent
model,12 adding a resistive inspiratory load in order to train
the inspiratory muscles has shown promising results for pa-
tients in small series115–117 and improved weaning outcome
in a randomized trial.118
The period of controlled mechanical ventilation should be
kept short.82,119 Ventilation modes with sustained patient
effort should be introduced early,39 as can be inferred from
various animal experiments. Assist Control Ventilation
modes (controlled mechanical ventilation with the possibil-
ity to trigger additional breaths) and pressure support venti-
lation (patient’s breathing efforts supported by a preset
pressure) may attenuate VIDD in animals.9,109 Nevertheless,
partial supportive modes can still cause VIDD in the setting
of over-assist,8 so mode per se is not protective. On the con-
trary, in septic rabbits, controlled mechanical ventilation
may protect from VIDD61 and the use of modes that allow
spontaneous breathing is contradictory to the documented
beneﬁt of neuromuscular blockers in the early course of se-
vere acute respiratory distress syndrome (ARDS).120
The preferred ventilation mode, the optimal level of sup-
port (‘unloading’), or the rate of support reduction for pa-
tients is currently unknown.39 Spontaneous breathing is well
maintained with so-called effort adapted modes121 like neu-
rally adjusted ventilatory assist (NAVA) or adaptive support
ventilation (ASV). ASV seems to mitigate deleterious effects
of mechanical ventilation on the diaphragm of piglets.10
NAVA delivers assist in unison with the patient’s inspiratory
neural effort.93 As the support level is titrated against the pa-
tient’s respiratory demand, patients are protected against
over-assist.122,123 This approach was successfully used in var-
ious clinical ICU settings97,122,124,125 but most importantly in
patients with critical illness myo-neuropathy.97
Currently, no medical treatment for VIDD is available.126
Anti-oxidants show beneﬁts in animal models40,71,72,127
and in a randomized trial in critically ill surgical patients.128
However, human data remain sparse. Targeting of proteo-
lytic (especially proteasome) pathways in rodent models
may further elucidate the pathophysiology and theoretically
open novel therapeutic avenues. Inhibition of lysosomal
proteases and calpain with leupeptin129 or the proteasome
using bortezomib130 may be of interest as data indicate
potential to completely or partially prevent VIDD. However,
results could not be reproduced with epoxomicin.131 Over-
all, effects may be time dependent.129–132 Moreover, R548,
a JAK/STAT inhibitor, maintained normal diaphragmatic con-
tractility,133 and a recent FOXO (forkhead BoxO) animal
knockout model suggests new potential therapeutic
targets.134
While the effects of corticosteroids on VIDD seem dose de-
pendent conﬂicting,135,136 propofol was accused as a causa-
tive agent in animal models.137 Neuromuscular blockers do
not to have additive effects on diaphragmatic dysfunction.136
Moreover, moderate hypercapnia exerts protective effects on
diaphragmatic muscular strength,138,139 which ﬁts to the
overall concept of lung protective ventilation.140 In addition,
the calcium sensitizer Levosimendan may improve diaphrag-
matic neuro-mechanical efﬁciency in healthy volunteers,
while the fast skeletal troponin activator CK-2066260
Figure 2 Assessment of (A) expiratory and (B) inspiratory diaphragmatic
thickness (brightness mode, linear array high frequency transducer of
>10Mhz, zone of apposition: mid-axillary line). Note in- and expiratory
variation (limits of normal may vary).102,108 The thickening fraction [i.e.
(inspiratory–expiratory diameter) / expiratory diameter] can be
assessed.143 Maximum diameters are measured between diaphragmatic
pleural line (*) and peritoneal line (#). Central diaphragmatic tendon
(c). Liver (L), Lungs (P) are indicated.
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improved diaphragmatic ﬁbre strength ex vivo in an experi-
mental human trial.24 Further studies in critically ill patients
with respiratory failure are warranted.141
In conclusion, prolonged periods of complete diaphrag-
matic rest should be avoided and diaphragmatic contractions
preserved whenever possible. Respiratory muscle training
may lead to improved weaning success.
Respiratory muscle dysfunction in
critically ill patients: summary and
outlook
Ventilator-induced diaphragmatic dysfunction is an
established and speciﬁc ‘side effect’ of prolonged mechanical
ventilation. The clinical hallmark is respiratory muscle weak-
ness which contributes to weaning failure and thus implies
a signiﬁcant health care burden. Major pathophysiological
changes are disuse atrophy and microstructural changes in-
cluding decreased protein synthesis, increased proteolysis,
and oxidative stress, possibly linked to mitochondrial
dysfunction.
For the clinician, bedside ultrasound evaluation and as-
sessment of the electrical diaphragmatic activity are promis-
ing tools for the diagnosis and monitoring of respiratory
muscle dysfunction/VIDD. Respiratory muscle training may
have beneﬁcial effects. Questions remain about the optimal
strategy and mode of mechanical ventilation for affected pa-
tients. Effort adapted ventilation modes may offer advan-
tages. Whether this may lead to improved clinical outcomes
needs to be established.
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